Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMS-103HP
- Development stage
- Discontinued
- Lead developer
- Omeros
- Modality
- Small Molecules
- Administration
- Intraarticular, Irrigation
01
Overview
OMS-103HP is a PharmacoSurgery product candidate developed by Omeros Corporation, designed for use during arthroscopic procedures such as partial meniscectomy and anterior cruciate ligament (ACL) reconstruction. It is a proprietary combination of three small-molecule drugs: ketorolac (a non-steroidal anti-inflammatory drug), amitriptyline (a tricyclic antidepressant), and oxymetazoline (an alpha-adrenergic agonist). The drug is added to standard irrigation solutions used during surgery to deliver therapeutic agents directly to the surgical site. Its mechanism of action involves the preemptive inhibition of inflammation and pain by targeting cyclooxygenase enzymes and providing local analgesia, while oxymetazoline acts as a vasoconstrictor to reduce bleeding and potentially prolong the local effect of the other components. Although OMS-103HP successfully completed Phase 3 clinical trials, its commercialization was halted following a licensing dispute with Fagron, which failed to meet its commercialization obligations.
- Brand names
- OMS103OMS-103OMS 103
- Other names
- Oms 103HPOms103HPOms-103HP
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)ADRA2A (α2A)ADRA1A (α1A)NaV (Voltage-gated sodium channels)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on OMS-103HP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMS-103HP.